150 related articles for article (PubMed ID: 24570340)
1. Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.
Vigan M; Stirnemann J; Mentré F
AAPS J; 2014 May; 16(3):415-23. PubMed ID: 24570340
[TBL] [Abstract][Full Text] [Related]
2. Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.
Plan EL; Maloney A; Mentré F; Karlsson MO; Bertrand J
AAPS J; 2012 Sep; 14(3):420-32. PubMed ID: 22528503
[TBL] [Abstract][Full Text] [Related]
3. Performance in population models for count data, part II: a new SAEM algorithm.
Savic R; Lavielle M
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):367-79. PubMed ID: 19680795
[TBL] [Abstract][Full Text] [Related]
4. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.
Samson A; Lavielle M; Mentré F
Stat Med; 2007 Nov; 26(27):4860-75. PubMed ID: 17562540
[TBL] [Abstract][Full Text] [Related]
5. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
6. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Berger J; Vigan M; Pereira B; Nguyen TT; Froissart R; Belmatoug N; Dalbiès F; Masseau A; Rose C; Serratrice C; Pers YM; Bertchansky I; Camou F; Bengherbia M; Bourgne C; Caillaud C; Pettazzoni M; Berrahal A; Stirnemann J; Mentré F; Berger MG
Clin Pharmacokinet; 2019 Apr; 58(4):469-482. PubMed ID: 30128966
[TBL] [Abstract][Full Text] [Related]
7. Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.
Savic RM; Mentré F; Lavielle M
AAPS J; 2011 Mar; 13(1):44-53. PubMed ID: 21063925
[TBL] [Abstract][Full Text] [Related]
8. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
9. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
10. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
11. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
12. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
Lin HY; Lin SP; Chuang CK; Wraith JE
J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
[TBL] [Abstract][Full Text] [Related]
15. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
16. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
18. Performance of three estimation methods in repeated time-to-event modeling.
Karlsson KE; Plan EL; Karlsson MO
AAPS J; 2011 Mar; 13(1):83-91. PubMed ID: 21229340
[TBL] [Abstract][Full Text] [Related]
19. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM
Sukarnjanaset W; Wattanavijitkul T; Jarurattanasirikul S
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):729-736. PubMed ID: 29785609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
